Posted by SLS on June 28, 2012, at 14:07:16
In reply to Re: D2 (D3) agonists' capacity to flatten affect, posted by psychobot5000 on June 28, 2012, at 13:09:49
> I am unsure whether there might be a dosing regimen of agents with D3 (a 'D2-like' receptor) that might prevent or supercede this phenomenon, i.e. perhaps with higher doses.
Very possibly. The dosage-response curve of apomorphine, comprising sedation followed by hyperlocomotion, is an example of this.
Aripiprazole and cariprazine are partial D2/D3 agonists that seem not to have a pervasive effect of the flattening of mood at low dosages. Infrequently, these drugs can blunt cognition and affect at high dosages.
- ScottSome see things as they are and ask why.
I dream of things that never were and ask why not.- George Bernard Shaw
poster:SLS
thread:1019496
URL: http://www.dr-bob.org/babble/20120608/msgs/1020333.html